- Company
- Enhertu redefines the standard in early-stage breast cancer
- by Hwang, byoung woo Oct 20, 2025 06:08am
- The antibody-drug conjugate (ADC) Enhertu (trastuzumab deruxtecan, T-DXd) has taken center stage as a new cornerstone in the treatment strategy for early-stage breast cancer. Both the DESTINY-Breast05 and DESTINY-Breast11 trial results that were presented at the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin showed signi
- Company
- 'Keytruda+Padcev' proposed as a new standard trt for MIBC
- by Hwang, byoung woo Oct 20, 2025 06:07am
- Keytruda (pembrolizumab) and Padcev (enfortumab vedotin) have demonstrated synergistic effects in muscle-invasive bladder cancer (MIBC), opening up new possibilities. Analysis suggests that the combination of enfortumab vedotin and pembrolizumab may shift the perioperative standard of care for MIBC patients who are ineligible for or refuse ci
- Company
- Alecensa achieves 81-month median overall survival
- by Hwang, byoung woo Oct 20, 2025 06:07am
- Roche's ALK inhibitor Alecensa (alectinib) has demonstrated long-term survival benefits exceeding 7 years in patients with ALK-positive advanced non-small cell lung cancer (NSCLC). In the final overall survival (OS) analysis of the Phase III ALEX study, Alecensa showed a clear survival benefit over existing treatments, reaffirming its status
- Company
- Ipsen's Bylvay is officially launched in Korea
- by Son, Hyung Min Oct 20, 2025 06:06am
- &160;Ipsen Korea is introducing a treatment for progressive familial intrahepatic cholestasis (PFIC), an extremely rare hereditary liver disease, to the domestic market. This launch opens new hope for pediatric patients who previously had no treatment option beyond liver transplantation. Bylvay has been selected as the first product unde
- Company
- Rosuzet and K-CAB maintain dual lead…Paxlovid sales surge
- by Chon, Seung-Hyun Oct 17, 2025 06:18am
- Homegrown drugs continue to dominate the top ranks of the outpatient prescription market. Quarterly outpatient prescriptions of the new combination therapy Rosuzet and the new drug K-CAB both surpassed KRW 50 billion, firmly maintaining a two-top system. Meanwhile, Livalozet continued its steep growth trajectory, and Paxlovid saw a sharp rise in
- Opinion
- [Reporter's View] Transparent info, the key to vaccine trust
- by Son, Hyung Min Oct 17, 2025 06:11am
- Starting on the 15th of this month, simultaneous administration of COVID-19 and influenza perioperative vaccines has begun for older adults aged 65 and older and high-risk groups. The Korea Disease Control and Prevention Agency (KDCA) has informed that the rate of adverse events from simultaneous vaccination does not exceed that seen with
- Company
- DLBCL drug Monjuvi may be prescribed at Big 5 Hospitals
- by Eo, Yun-Ho Oct 17, 2025 06:11am
- Handok's newly introduced drug ‘Monjuvi’ may now be prescribed at tertiary hospitals in Korea. According to industry sources, Monjuvi (tafasitamab), a treatment for diffuse large B-cell lymphoma (DLBCL) introduced by Handok from Incyte, has passed the Drug Committee (DC) reviews at the Big 5 medical institutions in Korea - Samsung Medic
- Company
- "Switzerland and Korea partner up for bio-ecosystem"
- by Son, Hyung Min Oct 17, 2025 06:11am
- As the global pharmaceutical industry is restructuring around collaboration, Switzerland and South Korea are strengthening their partnership to build an innovation ecosystem. The vision is to establish a model of joint innovation, based on efficient resource and mutual trust, rather than a simple technology exchange. On October 16, Roche
- Policy
- Keytruda, Dupixent begin negotiations for reimb expansions
- by Jung, Heung-Jun Oct 17, 2025 06:10am
- The immuno-oncology drug Keytruda (pembrolizumab) and the atopic dermatitis treatment Dupixent Pre-filled (dupilumab) have entered price negotiations, moving one step closer to expanding reimbursement in Korea. Both MSD Korea’s Keytruda and Sanofi-Aventis Korea’s Dupixent received reviews deeming reimbursement adequate for expanded indi
- Policy
- "Korea Passing concerns…'dual pricing system' under review"
- by Lee, Jeong-Hwan Oct 17, 2025 06:10am
- Minister of Health and Welfare Jeong Eun Kyeong announced that the Ministry would strengthen administrative efforts for 'fast track National Health Insurance (NHI) listing of new drugs' and review the introduction of a 'dual pricing system' to prevent global pharmaceutical companies from "Korea Passing" of their new drugs. On October 14,
